Half of patients who die from prostate cancer have metastases at diagnosis
the ONA take:
According to a new study published in the journal Prostate Cancer & Prostatic Diseases, researchers sought to determine which types of patients die from prostate cancer in the modern era.
The researchers identified 190 men with metastatic castration-resistant prostate cancer (CRPC) treated between 2008 and 2011 and analyzed the characteristics of the 113 patients who died as a result of prostate cancer.
Of the 113 patients, 56% had identifiable metastases at the time of diagnosis. Of those, 67% had bone metastases, 111% had visceral metastases, and 43% had lymph node metastases. The median time to developing CRPC was 16 months and the median overall survival was approximately 5.2 years.
Among patients who died from prostate cancer, 46% of those initially diagnosed with localized disease had T stage ≥3 and 38% had a Gleason score ≥8. Overall, 26% had a Gleason score ≤6 and 64% were classified as having high-risk prostate cancer. The median overall survival was found to be 8.8 years.
The findings suggest that among those who die from prostate cancer, about half have detectable metastases at diagnosis. Therefore, the researchers recommend that more future studies should be conducted in patients with newly diagnosed metastatic prostate cancer.
researchers sought to determine which types of patients die from prostate cancer in the modern era.
The authors used two monthly curated databases of patients with castration–resistant prostate cancer (CRPC) to describe the natural history of patients dying of CaP in the modern era. In the modern era, approximately half of the patients who die from CaP have metastases at diagnosis.
The paradigm of progression from localized disease to metastasis and eventually death is only represented in the other half, although possible initial screening and staging errors ought to be taken into consideration. More efforts are needed to conduct trials in patients with newly diagnosed metastatic CaP.
- Novel Colonoscopy Prep Is Poised to Improve Screening Rates for Colon Cancer
- PPIs Negatively Impact Outcomes of Patients Treated With Capecitabine
- How Physical Changes From Breast Cancer Affect Self-Image: Considerations for Clinicians
- Panobinostat Modestly Improves OS in Relapsed Multiple Myeloma
- Short-Term Intervention May Have Long-term Diet Effect in Hispanic Breast Cancer Survivors
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Implementing a Distress Screening Process for Cancer Patients
- Initiating Palliative Care in the Emergency Department
- New Research Identifies Potential Bladder Cancer Chemotherapy Side Effect
- Pseudohyperkalemia: False Potassium Levels Occur in a Patient With Lymphoma
- Atezolizumab Granted FDA Approval for Specific Cases of NSCLC
- Low-Dose Sublingual Fentanyl Safe, Effective in Patients Receiving Lower Opioid Doses
- High U.S. Economic Burden for Vaccine-Preventable Diseases
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|